Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical data, FDA timelines, and cash-burn tables is time-consuming. Acadia Pharmaceuticals’ SEC reports often run hundreds of pages, making it difficult to spot when a Parkinson’s Disease Psychosis trial hits a safety milestone or how Rett syndrome R&D spend affects guidance. That’s the problem we solve.
Stock Titan delivers AI-powered summaries that turn complex disclosures into plain language. Need the Acadia Pharmaceuticals quarterly earnings report 10-Q filing? Our platform extracts revenue by franchise, cash runway, and trial expense in seconds. Curious about Acadia Pharmaceuticals insider trading Form 4 transactions? Real-time alerts flag every executive stock move so you can track patterns before the market reacts.
- Acadia Pharmaceuticals annual report 10-K simplified—understand pipeline progress and risk factors without reading 200 pages.
- Acadia Pharmaceuticals Form 4 insider transactions real-time—follow buys, sells, and option exercises instantly.
- Acadia Pharmaceuticals proxy statement executive compensation—see how trial milestones tie to pay packages.
- Acadia Pharmaceuticals 8-K material events explained—AI highlights FDA decisions, partnership deals, and financing updates.
Whether you’re understanding Acadia Pharmaceuticals SEC documents with AI or seeking a quick Acadia Pharmaceuticals earnings report filing analysis, every form—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed and updated in real time directly from EDGAR. Stop scrolling; start focusing on what moves ACAD’s valuation.
Acadia Pharmaceuticals director Elizabeth A. Garofalo reported a sale of 1,600 shares of Acadia common stock on 09/02/2025 at a weighted average price of $25.9753. Following the sale, the reporting person beneficially owned 25,382 shares. The filer notes the reported price is a weighted average for multiple transactions that ranged from $25.97 to $25.991 and offers to provide details on quantities sold at each price upon request. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Mark C. Schneyer, EVP and Chief Financial Officer of Acadia Pharmaceuticals (ACAD), reported the sale of 22,000 shares of the issuer's common stock on 08/18/2025 at a weighted-average price of $25.1829 per share, with sale prices in the range $25.06 to $25.28. Following the reported disposition, Mr. Schneyer beneficially owned 40,130 shares. The Form 4 discloses the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The filing was signed on behalf of the reporting person by an attorney-in-fact on 08/19/2025.
Acadia Pharmaceuticals (ACAD) filing a Form 144 to notify a proposed sale of securities. The notice identifies 22,000 shares of common stock to be sold through Piper Sandler & Co. on or about 08/18/2025, with an aggregate market value of $557,260.00. The filing shows the shares were acquired as compensation from the issuer on 11/17/2023 and payment was recorded on that date. The filing lists total shares outstanding as 168,712,220. Several standard filer and issuer identification fields in the form are blank, and no name is provided for the person on whose account the sale will occur.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
